Literature DB >> 8903093

Classification, pathogenesis, and treatment of systemic vasculitis.

M E Griffith1, G Gaskin, C D Pusey.   

Abstract

Patients with systemic vasculitis (SV), especially Wegener's granulomatosis and microscopic polyangiitis, regularly present with renal involvement. Although considered a rare disease, either the incidence of SV is increasing or it is being increasingly recognized. Accurate classification systems are required to allow comparison of data from different groups investigating and treating these patients. Systemic vasculitis is known to be an autoimmune disease, but the mechanisms of pathogenesis have not been established, despite many studies on this topic in recent years. Most of this work has been done in vitro, although development of animal models is underway. Patient and renal survival have improved with aggressive immunosuppressive treatment, but morbidity is high and controversies remain in establishing the most effective regimens with minimum adverse effects. In this review we discuss the classification of SV, review the current knowledge of pathogenic mechanisms, and consider the relative merits of different treatment protocols.

Entities:  

Mesh:

Year:  1996        PMID: 8903093     DOI: 10.3109/08860229609047707

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  3 in total

Review 1.  Cellular aspects of vasculitis--T cell-mediated aspects.

Authors:  M E Griffith; C D Pusey
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Animal models of vasculitides.

Authors:  Uriel Katz; Boris Gilburd; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

3.  Anti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site.

Authors:  M E Griffith; A Coulthart; S Pemberton; A J George; C D Pusey
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.